Portal:Disease/COVIDPathways
From WikiPathways
(Split up the page a bit further into two sections: one about specifically SARS-CoV-2 and one about coronavirus pathways in general.) |
Current revision (17:55, 15 September 2020) (view source) (Redirecting to Portal:COVID-19) |
||
(13 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
+ | #REDIRECT [[Portal:COVID-19]] | ||
+ | |||
__NOTOC__ | __NOTOC__ | ||
+ | |||
{|style="margin: 10px;" | {|style="margin: 10px;" | ||
|width=800px| | |width=800px| | ||
<br/><big><font color="#407F7F" size="5">Welcome to the COVID-19 Pathway Collection</font></big><br/><br/> | <br/><big><font color="#407F7F" size="5">Welcome to the COVID-19 Pathway Collection</font></big><br/><br/> | ||
<p>This special subset of disease pathways is being highlighted during the current COVID-19 crisis. This content is released under a CC0 waiver to be freely used, reused and distributed. Let us know if you add a new pathway or want to recommend one for this collection.</p> | <p>This special subset of disease pathways is being highlighted during the current COVID-19 crisis. This content is released under a CC0 waiver to be freely used, reused and distributed. Let us know if you add a new pathway or want to recommend one for this collection.</p> | ||
- | <p>The current list of authors and contributors of content of this portal: [[User:Fehrhart|Friederike Ehrhart]], [[User:AlexanderPico|Alex Pico]], [[User:Khanspers|Kristina Hanspers]], [[User:Amber|Amber Koning]], [[User:Rex_D_A_B|Rex D A B]], [[User:Penny|Penny Nymark]], [[User:DeSl|Denise Slenter]], [[User:C.F.Thorn|Caroline Thorn]], the Reactome project, [[User:Evelo|Chris Evelo]], [[User:L Dupuis|Lauren Dupuis]], [[User:Conroy_lipids|Matthew Conroy]], [[User:Mkutmon|Martina Kutmon]], [[User:Marvin M2|Marvin Martens]], and many more.</p> | + | <p>The current list of authors and contributors of content of this portal: [[User:Fehrhart|Friederike Ehrhart]], [[User:AlexanderPico|Alex Pico]], [[User:Khanspers|Kristina Hanspers]], [[User:Amber|Amber Koning]], [[User:Rex_D_A_B|Rex D A B]], [[User:Penny|Penny Nymark]], [[User:DeSl|Denise Slenter]], [[User:C.F.Thorn|Caroline Thorn]], [[User:Jdoijen|Jordi Doijen]], the Reactome project, [[User:Evelo|Chris Evelo]], [[User:L Dupuis|Lauren Dupuis]], [[User:Conroy_lipids|Matthew Conroy]], [[User:Mkutmon|Martina Kutmon]], [[User:Marvin M2|Marvin Martens]], and many more.</p> |
<p>We also thank the authors of all the cited articles (recursively).</p> | <p>We also thank the authors of all the cited articles (recursively).</p> | ||
Line 16: | Line 19: | ||
{| style="margin: 10px; background-color:#AFDCDE" | {| style="margin: 10px; background-color:#AFDCDE" | ||
|width=100px; cell padding=50px|{{#pwImage:Pathway:WP4846|250px||SARS-CoV-2 and COVID-19 Pathway}} | |width=100px; cell padding=50px|{{#pwImage:Pathway:WP4846|250px||SARS-CoV-2 and COVID-19 Pathway}} | ||
- | Collaborative project for curation biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. | + | Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. |
|width=100px|{{#pwImage:Pathway:WP4860|250px||Hijack of Ubiquitination by SARS-CoV-2}} | |width=100px|{{#pwImage:Pathway:WP4860|250px||Hijack of Ubiquitination by SARS-CoV-2}} | ||
SARS-CoV-2 includes a novel Orf10 that interacts with muliple members of the Cullin 2 ubiquitin ligase complex. | SARS-CoV-2 includes a novel Orf10 that interacts with muliple members of the Cullin 2 ubiquitin ligase complex. | ||
- | |||
|width=100px|{{#pwImage:Pathway:WP4868|250px||Type I Interferon Induction and Signaling During SARS-CoV-2 Infection}} | |width=100px|{{#pwImage:Pathway:WP4868|250px||Type I Interferon Induction and Signaling During SARS-CoV-2 Infection}} | ||
The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. | The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. | ||
+ | |width=100px|{{#pwImage:Pathway:WP4927|250px||COVID-19, thrombosis and anticoagulation}} | ||
|- | |- | ||
|} | |} | ||
Line 36: | Line 39: | ||
{| style="margin: 10px; background-color:#AFDCDE" | {| style="margin: 10px; background-color:#AFDCDE" | ||
|width=100px|{{#pwImage:Pathway:WP4904|250px||LDLRAD4 pathway in COVID-19}} | |width=100px|{{#pwImage:Pathway:WP4904|250px||LDLRAD4 pathway in COVID-19}} | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4936|250px||Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens)}} |
- | | | + | |width=100px|{{#pwImage:Pathway:WP4961|250px||STING pathway in Kawasaki-like disease and COVID-19 (Homo sapiens)}} |
|- | |- | ||
|} | |} | ||
- | == Other coronaviruses: MERS, SARS-CoV | + | == Other coronaviruses: MERS, SARS-CoV, etc == |
{| style="margin: 10px; background-color:#AFDCDE" | {| style="margin: 10px; background-color:#AFDCDE" | ||
|width=100px|{{#pwImage:Pathway:WP4853|250px||Coronavirus lipid metabolism}} | |width=100px|{{#pwImage:Pathway:WP4853|250px||Coronavirus lipid metabolism}} | ||
Lipid metabolism alternations that are related to infection by the corona virus. | Lipid metabolism alternations that are related to infection by the corona virus. | ||
- | |||
|width=100px|{{#pwImage:Pathway:WP4863|250px||Host-pathogen interaction of human corona viruses - autophagy}} | |width=100px|{{#pwImage:Pathway:WP4863|250px||Host-pathogen interaction of human corona viruses - autophagy}} | ||
|width=100px|{{#pwImage:Pathway:WP4864|250px||Host-pathogen interaction of human corona viruses - apoptosis}} | |width=100px|{{#pwImage:Pathway:WP4864|250px||Host-pathogen interaction of human corona viruses - apoptosis}} | ||
+ | |width=100px|{{#pwImage:Pathway:WP4912|250px||SARS coronavirus and innate immunity}} | ||
|- | |- | ||
|} | |} | ||
{| style="margin: 10px; background-color:#AFDCDE" | {| style="margin: 10px; background-color:#AFDCDE" | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4861|250px||ER stress response in Coronavirus infection}} |
|width=100px|{{#pwImage:Pathway:WP4799|250px||Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein}} | |width=100px|{{#pwImage:Pathway:WP4799|250px||Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein}} | ||
|width=100px|{{#pwImage:Pathway:WP4877|250px||Host-pathogen interaction of human corona viruses - MAPK signaling}} | |width=100px|{{#pwImage:Pathway:WP4877|250px||Host-pathogen interaction of human corona viruses - MAPK signaling}} | ||
Line 59: | Line 62: | ||
|} | |} | ||
{| style="margin: 10px; background-color:#AFDCDE" | {| style="margin: 10px; background-color:#AFDCDE" | ||
- | |width=100px|{{#pwImage:Pathway: | + | |width=100px|{{#pwImage:Pathway:WP4965|250px||Deregulation of the Renin Angiotensin system by Sars-CoV infection}} |
- | + | ||
|- | |- | ||
|} | |} | ||
- | |||
== More about ACE2 == | == More about ACE2 == | ||
Line 72: | Line 73: | ||
|- | |- | ||
|} | |} | ||
- | |||
- | |||
- |
Current revision
- REDIRECT Portal:COVID-19
This special subset of disease pathways is being highlighted during the current COVID-19 crisis. This content is released under a CC0 waiver to be freely used, reused and distributed. Let us know if you add a new pathway or want to recommend one for this collection. The current list of authors and contributors of content of this portal: Friederike Ehrhart, Alex Pico, Kristina Hanspers, Amber Koning, Rex D A B, Penny Nymark, Denise Slenter, Caroline Thorn, Jordi Doijen, the Reactome project, Chris Evelo, Lauren Dupuis, Matthew Conroy, Martina Kutmon, Marvin Martens, and many more. We also thank the authors of all the cited articles (recursively).
|
SARS-CoV-2 Pathways
Image does not exist Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. |
Image does not exist SARS-CoV-2 includes a novel Orf10 that interacts with muliple members of the Cullin 2 ubiquitin ligase complex. |
Image does not exist The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. |
Image does not exist |
Image does not exist Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. |
Image does not exist |
Image does not exist Experimental pathway to investigate overlap of virus-host interaction and adverse outcome pathways |
Image does not exist Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis |
Image does not exist |
Image does not exist |
Image does not exist |
Other coronaviruses: MERS, SARS-CoV, etc
Image does not exist Lipid metabolism alternations that are related to infection by the corona virus. |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
More about ACE2
Image does not exist |
Image does not exist |